Overview

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects

Status:
Recruiting
Trial end date:
2022-07-10
Target enrollment:
Participant gender:
Summary
This phase 1, randomized, double-blind, placebo-controlled study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of CSL730 administered by subcutaneous (SC) injection or SC infusion in healthy adult subjects.
Phase:
Phase 1
Details
Lead Sponsor:
CSL Behring